Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction

News

May 8, 2024
PRESS RELEASE: On May 7, 2024, a new research paper was published in Oncotarget, entitled, “Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.” continue reading »

Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy

News

May 6, 2024
PRESS RELEASE: On May 3, 2024, a new research paper was published in Oncotarget, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.” continue reading »

Oncotarget Sponsors 19th International p53 Workshop in Italy

News

April 29, 2024
PRESS RELEASE: Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024. continue reading »

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

News

April 16, 2024
PRESS RELEASE: On April 12, 2024, a new research paper was published in Oncotarget, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.” continue reading »

Synergistic Effects of Drug Combinations Targeting AML Cells

Oncotarget

April 11, 2024
In this new study, researchers investigated a promising new approach to acute myeloid leukemia (AML) therapy by combining multiple drugs to enhance cytotoxic effects on AML cells. continue reading »